[新技术评估中直接标准成本的计算：在急性髓细胞白血病治疗中的应用]
[Calculation of direct standard costs in the evaluation of new technologies: application to the treatment of acute myeloblastic leukemias].
作者信息
Viens-Bitker C, Blum C, Bessis M, Cordonnier C, Rochant H, Jolly D
出版信息
Rev Epidemiol Sante Publique. 1986;34(1):41-51.
PMID:3088684
Abstract
Financial incidence of new technology can be approached through the utilization of "direct standard cost". This method allows actualization of prices and permits the integration of new procedures. It is applied to acute non lymphoblastic leukemia.
摘要
新技术的财务影响可以通过使用“直接标准成本”来探讨。这种方法能够实现价格的更新，并允许纳入新的程序。它适用于急性非淋巴细胞白血病。
Zotero 插件